Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo

To date, there is no standard-of-care systemic therapy for the treatment of aggressive meningiomas. Receptor tyrosine kinases (RTK) are frequently expressed in aggressive meningiomas and are associated with poor survival. Ponatinib is a FDA- and EMA-approved RTK inhibitor and its efficacy in meningi...

Full description

Bibliographic Details
Main Authors: Tao Yu, Junguo Cao, Montadar Alaa Eddine, Mahmoud Moustafa, Andreas Mock, Cihan Erkut, Amir Abdollahi, Rolf Warta, Andreas Unterberg, Christel Herold-Mende, Gerhard Jungwirth
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/13/23/5898